Monday, January 5, 2015

Immunomedics Inc awarded fast track designation by FDA for Sacituzumab Govitecan (IMMU-132) for triple-negative breast cancer therapy

… treatment of patients with triple-negative breast cancer (TNBC) who have failed prior …
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)